FibroGen, Inc.
FibroGen, Inc. (FGEN) Stock Overview
Explore FibroGen, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
30.3M
P/E Ratio
-75.01
EPS (TTM)
$-30.00
ROE
0.05%
FGEN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of FibroGen, Inc. (FGEN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 80.25, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $1.03.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -75.01 and a market capitalization of 30.3M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Thane Wettig
225
409 Illinois Street, San Francisco, CA
2014